FindTrial
Sign In

ASP3082

DRUG3 trials

Sponsors

Institut Gustave Roussy, Astellas Pharma Global Development Inc., Gustave Roussy, Cancer Campus, Grand Paris

Conditions

Adult participants with metastatic PDAC with KRAS G12D mutationMetastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinomaMetastatic/Locally Advanced Non-Small-Cell Lung CancerMetastatic/Locally Pancreatic Ductal Adenocarcinoma

Phase 2

Phase 2, Multicenter, Open label, Platform Study investigating ASP3082 in patients with Metastatic/Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), with biomarker analysis to characterize response/resistance (UNLOCK ASP3082)
Not yet recruitingCTIS2025-522533-54-00
Institut Gustave RoussyMetastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma
Target: 60Updated: 2026-01-29
Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance
RecruitingNCT07483983
Gustave Roussy, Cancer Campus, Grand ParisMetastatic/Locally Advanced Non-Small-Cell Lung Cancer, Metastatic/Locally Pancreatic Ductal Adenocarcinoma
Start: 2026-03-25End: 2027-10-01Target: 60Updated: 2026-08-05

Phase 3

A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination with mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants with KRAS G12D-mutated Metastatic Pancreatic Adenocarcinoma
Not yet recruitingCTIS2025-523684-38-00
Astellas Pharma Global Development Inc.Adult participants with metastatic PDAC with KRAS G12D mutation
Target: 69Updated: 2026-06-11